News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
228,923 Results
Type
Article (7196)
Company Profile (16)
Press Release (221711)
Multimedia
Podcasts (3)
Webinars (1)
Section
Business (63151)
Career Advice (295)
Deals (14774)
Drug Delivery (28)
Drug Development (36815)
Employer Resources (24)
FDA (6416)
Job Trends (4912)
News (121850)
Policy (11632)
Tag
Academia (569)
Accelerated approval (2)
Adcomms (7)
Allergies (38)
Alliances (14793)
ALS (29)
Alzheimer's disease (602)
Antibody-drug conjugate (ADC) (47)
Approvals (6464)
Artificial intelligence (110)
Autoimmune disease (10)
Automation (3)
Bankruptcy (147)
Best Places to Work (4611)
BIOSECURE Act (2)
Biosimilars (21)
Biotechnology (18)
Bladder cancer (57)
Brain cancer (15)
Breast cancer (117)
Cancer (1216)
Cardiovascular disease (73)
Career advice (260)
Career pathing (4)
CAR-T (93)
Cell therapy (225)
Cervical cancer (13)
Clinical research (31306)
Collaboration (318)
Compensation (94)
Complete response letters (7)
COVID-19 (729)
CRISPR (19)
C-suite (81)
Cystic fibrosis (38)
Data (1410)
Denatured (1)
Depression (21)
Diabetes (114)
Diagnostics (2237)
Digital health (5)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (48)
Drug pricing (42)
Drug shortages (17)
Duchenne muscular dystrophy (42)
Earnings (33636)
Editorial (15)
Employer branding (1)
Employer resources (19)
Events (31235)
Executive appointments (254)
FDA (7198)
Friedreich's ataxia (2)
Frontotemporal dementia (5)
Funding (277)
Gene editing (48)
Generative AI (10)
Gene therapy (139)
GLP-1 (187)
Government (1254)
Grass and pollen (2)
Guidances (115)
Healthcare (6141)
Huntington's disease (5)
IgA nephropathy (16)
Immunology and inflammation (40)
Indications (17)
Infectious disease (792)
Inflammatory bowel disease (67)
Inflation Reduction Act (5)
Influenza (25)
Intellectual property (55)
Interviews (46)
IPO (8048)
IRA (17)
Job creations (571)
Job search strategy (221)
Kidney cancer (8)
Labor market (5)
Layoffs (41)
Leadership (4)
Legal (2100)
Liver cancer (41)
Lung cancer (168)
Lymphoma (86)
Machine learning (3)
Management (7)
Manufacturing (110)
MASH (42)
Medical device (4592)
Medtech (4593)
Mergers & acquisitions (7104)
Metabolic disorders (289)
Multiple sclerosis (43)
NASH (8)
Neurodegenerative disease (25)
Neuropsychiatric disorders (4)
Neuroscience (823)
NextGen: Class of 2025 (1500)
Non-profit (712)
Obesity (139)
Opinion (77)
Ovarian cancer (57)
Pain (42)
Pancreatic cancer (53)
Parkinson's disease (68)
Partnered (5)
Patents (144)
Patient recruitment (69)
Peanut (17)
People (14557)
Pharmaceutical (8)
Pharmacy benefit managers (7)
Phase I (10000)
Phase II (13785)
Phase III (10326)
Pipeline (884)
Policy (34)
Postmarket research (796)
Preclinical (3674)
Press Release (9)
Prostate cancer (53)
Psychedelics (11)
Radiopharmaceuticals (119)
Rare diseases (160)
Real estate (1008)
Recruiting (7)
Regulatory (9197)
Reports (13)
Research institute (510)
Resumes & cover letters (39)
Rett syndrome (4)
RNA editing (2)
RSV (16)
Schizophrenia (29)
Series A (44)
Series B (34)
Service/supplier (2)
Sickle cell disease (23)
Special edition (2)
Spinal muscular atrophy (31)
Sponsored (14)
Startups (677)
Stomach cancer (5)
Supply chain (26)
Tariffs (4)
The Weekly (1)
Vaccines (174)
Venture capitalists (5)
Weight loss (76)
Women's health (6)
Worklife (4)
Date
Last 7 days (530)
Last 30 days (1482)
Last 365 days (15622)
2025 (5568)
2024 (16925)
2023 (19106)
2022 (22246)
2021 (23653)
2020 (21803)
2019 (14446)
2018 (10640)
2017 (11455)
2016 (9542)
2015 (11736)
2014 (8102)
2013 (5877)
2012 (6040)
2011 (6749)
2010 (6216)
Location
Africa (176)
Alabama (17)
Alaska (2)
Arizona (55)
Arkansas (3)
Asia (17600)
Australia (4857)
California (3096)
Canada (1169)
China (254)
Colorado (127)
Connecticut (171)
Delaware (64)
Europe (28135)
Florida (456)
Georgia (71)
Idaho (6)
Illinois (219)
India (20)
Indiana (128)
Japan (98)
Kansas (15)
Kentucky (6)
Louisiana (5)
Maine (36)
Maryland (373)
Massachusetts (2189)
Michigan (52)
Minnesota (109)
Missouri (36)
Montana (11)
Nebraska (8)
Nevada (45)
New Hampshire (36)
New Jersey (1059)
New Mexico (3)
New York (972)
North Carolina (407)
North Dakota (2)
Northern California (1382)
Ohio (67)
Oklahoma (1)
Oregon (7)
Pennsylvania (712)
Puerto Rico (8)
Rhode Island (8)
South America (302)
South Carolina (14)
Southern California (1191)
Tennessee (45)
Texas (470)
United States (11303)
Utah (75)
Virginia (82)
Washington D.C. (19)
Washington State (353)
West Virginia (2)
Wisconsin (12)
228,923 Results for "vaccitech limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
Vaccitech plc announced its financial results for the second quarter of 2023 and provided an overview of the Company’s progress.
August 10, 2023
·
13 min read
Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023
Vaccitech plc today announced it will host a Key Opinion Leader (KOL) Webinar to discuss the current treatment landscape for people living with chronic Hepatitis B Virus (HBV) infection.
September 13, 2023
·
5 min read
Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer
Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer will present data from its Phase 2 Hepatitis B trials of VTP-300.
November 6, 2023
·
8 min read
Business
Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments
Vaccitech plc (NASDAQ: VACC) (the Company, we or us) today announced its financial results for the first quarter of 2023 and an overview of the Company’s progress.
May 12, 2023
·
14 min read
Publication in Cell Shows That Vaccitech’s SNAPvax™ Has the Potential to Treat Cancer by Reversing Suppressive Tumor Microenvironment with Novel “Vax-Innate” Paradigm
Vaccitech plc announced the publication of research in preclinical animal models demonstrating the potential of Vaccitech’s SNAPvax for use in a novel paradigm for cancer treatment referred to as “VAX-INNATE.”
October 27, 2022
·
6 min read
Business
Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments
Vaccitech plc today announced its financial results for year end 2022 and an overview of the Company’s progress.
March 24, 2023
·
18 min read
Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B
Vaccitech plc will present positive final data from the HBV002 clinical trial at the European Association for the Study of the Liver (EASL) Congress 2023.
June 21, 2023
·
10 min read
Press Releases
Health Canada approves IMFINZI® (durvalumab) as the first and only immunotherapy regimen for adult patients with limited-stage small cell lung cancer (LS-SCLC)
April 10, 2025
·
6 min read
Business
Vaccitech Appoints Industry Veteran, Nadège Pelletier, Ph.D., as Chief Scientific Officer
Vaccitech plc today announced the appointment of Nadège Pelletier, Ph.D., as Chief Scientific Officer (CSO).
January 30, 2023
·
4 min read
Drug Development
Vaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical Lesions
Vaccitech plc today announced topline interim data from the HPV001 study (NCT04607850), a Phase 1b/2 clinical trial of VTP-200 in women with low-grade cervical human papillomavirus (HPV) lesions.
March 20, 2023
·
6 min read
1 of 22,893
Next
